A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Inclusion Criteria: Adult participants must be 18 years of age or older Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors Have documented evidence of genetic alterations conferring homologous recombination deficiency Participant must have progressed on at least one prior line of therapy in the advanced or metastatic setting that is considered an appropriate standard of care, or for which the participant has documented intolerance Exclusion Criteria: Known primary CNS malignancy Impairment of GI function or GI disease that may significantly alter the absorption of IDE161 Have active, uncontrolled infection Clinically significant cardiac abnormalities Major surgery within 4 weeks prior to enrollment Radiation therapy within 2 weeks prior to enrollment Systemic cytotoxic chemotherapy within 4 weeks prior to enrollment Radioimmunotherapy within 6 weeks of enrollment Treatment with a therapeutic antibody within 4 weeks prior to enrollment Treatment with an anti-cancer small molecule within 5 half-lives (t1/2), or 2 weeks, whichever is shorter